Cullinan Therapeutics, Inc.
CGEM
$20.34
$0.703.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.33M | 52.28M | 54.25M | 56.49M | 56.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 221.81M | 240.35M | 241.65M | 241.44M | 234.70M |
| Operating Income | -221.81M | -240.35M | -241.65M | -241.44M | -234.70M |
| Income Before Tax | -204.69M | -221.04M | -219.88M | -216.70M | -206.65M |
| Income Tax Expenses | -- | -- | -- | 117.00K | 117.00K |
| Earnings from Continuing Operations | -204.69 | -221.04 | -219.88 | -216.81 | -206.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 0.00 | 0.00 |
| Net Income | -204.69M | -221.04M | -219.88M | -216.81M | -206.76M |
| EBIT | -221.81M | -240.35M | -241.65M | -241.44M | -234.70M |
| EBITDA | -221.49M | -240.04M | -241.34M | -241.13M | -234.39M |
| EPS Basic | -3.28 | -3.53 | -3.52 | -3.48 | -3.32 |
| Normalized Basic EPS | -2.13 | -2.33 | -2.33 | -2.30 | -2.20 |
| EPS Diluted | -3.28 | -3.53 | -3.52 | -3.48 | -3.32 |
| Normalized Diluted EPS | -2.13 | -2.33 | -2.33 | -2.30 | -2.20 |
| Average Basic Shares Outstanding | 240.24M | 237.76M | 236.20M | 235.58M | 234.84M |
| Average Diluted Shares Outstanding | 240.24M | 237.76M | 236.20M | 235.58M | 234.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |